Salmeterol Xinafoate (SX) loaded into mucoadhesive solid lipid microparticles for COPD treatment
| Autor: | Donatella Valenti, Maria Letizia Manca, Elisabetta Pace, Maria Ferraro, Maria Luisa Bondì, Mark Gjomarkaj, Erika Amore, Serena Di Vincenzo, Valeria La Parola, Gaetano Giammona |
|---|---|
| Přispěvatelé: | Amore, Erika, Manca, Maria Letizia, Ferraro, Maria, Valenti, Donatella, La Parola, Valeria, Di Vincenzo, Serena, Gjomarkaj, Mark, Giammona, Gaetano, Bondì, Maria Luisa, Pace, Elisabetta |
| Rok vydání: | 2019 |
| Předmět: |
Agonist
Drug Alginates Cell Survival medicine.drug_class media_common.quotation_subject Sodium alginate polymer Pharmaceutical Science Chronic obstructive pulmonary disease (COPD) Inflammation 02 engineering and technology Pharmacology 030226 pharmacology & pharmacy Cell Line Pulmonary Disease Chronic Obstructive 03 medical and health sciences 0302 clinical medicine cAMP medicine Humans Aerodynamic diameter Adrenergic beta-2 Receptor Agonists Salmeterol Xinafoate media_common Drug Carriers COPD Inhalation Chemistry Therapeutic effect Adhesiveness 021001 nanoscience & nanotechnology medicine.disease Lipids SALMETEROL XINAFOATE Bronchodilator Agents respiratory tract diseases Salmeterol Xinafoate (SX) Mucus medicine.symptom 0210 nano-technology |
| Zdroj: | International journal of pharmaceutics 562 (2019): 351–358. doi:10.1016/j.ijpharm.2019.03.059 info:cnr-pdr/source/autori:Erika Amore; Maria Letizia Manca; Maria Ferraro; Donatella Valenti; Valeria La Parola; Serena Di Vincenzo; Mark Gjomarkaj; Gaetano Giammona; Maria Luisa Bondì; Elisabetta Pace/titolo:Salmeterol Xinafoate (SX) loaded into mucoadhesive solid lipid microparticles for COPD treatment/doi:10.1016%2Fj.ijpharm.2019.03.059/rivista:International journal of pharmaceutics (Print)/anno:2019/pagina_da:351/pagina_a:358/intervallo_pagine:351–358/volume:562 |
| ISSN: | 0378-5173 |
| Popis: | Chronic obstructive pulmonary disease (COPD) is one of the main health problems worldwide. It is characterised by chronic inflammation in the lungs that leads to progressive, chronic, largely irreversible airflow obstruction. The use of long-acting β agonists remain today the frontline treatment for COPD with the aim of minimizing side effects and enhancing therapeutic usefulness. To this purpose, in this paper, mucoadhesive solid lipid microparticles (SLMs) containing a long-acting β-2 agonist, Salmeterol Xinafoate (SX) were prepared, characterised (size, z-potential, aerodynamic diameter, turbidimetric evaluations, drug loading and entrapping efficiency) and tested in a model of bronchial epithelial cells. It was demonstrated that the incorporation of SX into SLMs led to the production of particles suitable for inhalation and more efficient than the free molecule at increasing the cAMP expression in bronchial epithelial cells. In conclusion, the prepared systems, due to their aerodynamic behaviour and mucoadhesive properties, could improve the retention time of SX in the lung epithelium and its therapeutic effect, thus representing a good strategy for the treatment of COPD patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect